Cancer Chemotherapy and Pharmacology

, Volume 36, Issue 5, pp 431–438 | Cite as

Cytotoxicity of antitumor platinum complexes withl-buthionine-(R, S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin

  • Sandra E. Brooks
  • Timothy T. Korbut
  • Norman P. Dupuis
  • Sylvia A. Holden
  • Beverly A. Teicher
Original Article Buthionine Sulfoximine, Etanidazole, Antitumor Platinum Complexes, Tetraplatin
Received:
Accepted:

Abstract

Human 2008 ovarian carcinoma cells and the C13 CDDP-resistant subline and human MCF-7 breast carcinoma cells and the MCF-7/CDDP CDDP-resistant subline were exposed tol-buthionine-(S, R)-sulfoximine (50 μM) for 48 h prior to and during exposure for 1 h to the antitumor platinum complexes,cis-diamminedichloroplatinum(II), carboplatin or D,L-tetraplatin and/or to etanidazole (1 mM) for 2 h prior to and during exposure for 1 to the antitumor platinum complexes. These modulators alone did not significantly alter the cytotoxicity of CDDP toward either parental line. A twofold enhancement in cytotoxicity was observed with carboplatin in the 2008 cells and with D,L-tetraplatin in both parental lines with the single modulators. The modulator combination (buthionine sulfoximine/etanidazole) was very effective along with D,L-tetraplatin in both the MCF-7 parent and MCF-7/CDDP cell lines where at the higher platinum complex concentrations there was 1.5 to 3 logs increased killing of cells by the drug plus the modulators compared with the drug alone. Similarly, when C13 cells were exposed to CDDP (100 μM) or D,L-tetraplatin (100 μM) along with buthionine sulfoximine and etanidazole there was a 2-log increase in cell killing compared with exposure to the platinum complex alone. Treatment of each of the four cell lines with buthionine sulfoximine decreased both the non-protein and total sulfhydryl content of the cells. Treatment with the combination of modulators did not produce a further decrease in cellular sulfhydryl content compared with buthionine sulfoximine alone. The total sulfhydryl content in MCF-7 cells and 2008 cells exposed to buthionine sulfoximine and etanidazole was 58% and 31% of normal and the total sulfhydryl content of MCF-7/CDDP cells and C13 cells treated the same way was 54% and 23% of normal, respectively. DNA alkaline elution was used to assess the impact of exposure to the modulators, buthionine sulfoximine and etanidazole, alone and in combination on the cross linking of DNA by the antitumor platinum complexes in the MCF-7 and MCF-7/CDDP cell lines. Overall, the increases in DNA cross linking factors were greater in the MCF-7 cells than in the MCF-7/CDDP cells. These results indicate a possible clinical potential for this modulator combination.

Key words

Buthionine sulfoximine Etanidazole Antitumor platinum complexes Tetraplatin 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alberts DS, Green SJ, Hannigan EV, O'Toole R, Mason-Liddll N, Surwit E, Stock-Novack D, Goldberg R, Malviya V, Nahhas W (1989) Improved efficacy of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: preliminary report by the Southeast Oncology Group of a phase III randomized trial in stages III and IV suboptimal ovarian cancer. Proc Am Soc Clin Oncol 8: 151Google Scholar
  2. 2.
    Andrews PA, Albright KD (1992) Mitochondrial defects incis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 52: 1895Google Scholar
  3. 3.
    Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990: 35Google Scholar
  4. 4.
    Andrews PA, Murphy MP, Howell SB (1985) Differential potentiation of alkylating and platinating agent toxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 45: 6250Google Scholar
  5. 5.
    Andrews PA, Mann SC, Huynh HH, Albright KD (1991) Role of the Na+,K+-adenosine triphosphatase in the accumulation ofcis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res 51: 3677Google Scholar
  6. 6.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR (1994) Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 12: 194Google Scholar
  7. 7.
    Batist G, Schectoer R, Woo A, Green D, Lehner S (1991) Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines. Biochem Pharmacol 41: 631Google Scholar
  8. 8.
    Bokkel Huinink WW ten, Rodenhuis S, Simonetti G, Dubbelman R, Franklin H, Dalesio O, Vermorken JB, McVie JG (1990) Studies with carboplatin in ovarian cancer: experience of the Netherlands Cancer Institute and GCCG of the European Organization for Research and Treatment of Cancer. In: Bunn, PA, Canetta, R, Ozols, RF, Rozencweig M (eds) Carboplatin (JM-8): current perspectives and future directions. Harcourt Brace Jovanovich, Philadelphia, p 165Google Scholar
  9. 9.
    Britten RA, Green JA, Broughton C, Browning PGW, White R, Warenius HM (1991) The relationship between nuclear glutathione levels and resistance to melphalan in human ovarian tumour cells. Biochem Pharmacol 41: 647Google Scholar
  10. 10.
    Calcutt G, Connors TA (1963) Tumor sulfhydryl levels and sensitivity to the nitrogen mustard melphalan. Biochem Pharmacol 12: 839Google Scholar
  11. 11.
    Carney DN, Teeling M (1990) Carboplatin plus cyclophosphamide for epithelial ovarian carcinoma. In: Bunn PA, Canetta, R, Ozols RF, Rozencweig M (eds) Carboplatin (JM-8): current perspectives and future directions. Harcourt Brace Jovanovich, Philadelphia, p 125Google Scholar
  12. 12.
    Chaney SG, Kaun-Till G, Poma A, Holbrook DJ (1989) Biotransformations of tetraplatin in rat plasma. Proc Am Assoc Cancer Res 30: 470Google Scholar
  13. 13.
    Chaney SG, Wyrick S, Till GK (1990) In vitro biotransformations of tetrachloro(D,L-trans)-1, diamminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res 50: 4539Google Scholar
  14. 14.
    Chen G, Waxman DJ (1994) Role of cellular glutathione and glutathioneS-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochem Pharmacol 47: 1079Google Scholar
  15. 15.
    Chen G, Zeller WJ (1991) Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anticancer Res 11: 2231Google Scholar
  16. 16.
    Coleman NC (1985) Hypoxic cell radiosensitizers: expectations and progress in drug development. Int J Radiat Oncol Biol Phys 11: 323Google Scholar
  17. 17.
    Dethmers JK, Meister A (1981) Glutathione export by human lymphoid cells: depletion of glutathione by inhibition of its synthesis decreases export and increases sensitivity to irradiation. Proc Natl Acad Sci U S A 78: 7492Google Scholar
  18. 18.
    Edwards PG (1988) Evidence that glutathione may determine the differential cell-cycle phase toxicity of a platinum(IV) antitumor agent. J Natl Cancer Inst 80: 734Google Scholar
  19. 19.
    Eisenhauer EA, Swenerton KD, Sturgeon JF, Fine S, O'Reilly SE (1986) Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 70: 1195Google Scholar
  20. 20.
    Franko AJ (1986) Misonidazole and other hypoxia markers. Metabolism and applications. Int J Radiat Oncol Biol Phys 12: 1195Google Scholar
  21. 21.
    Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC Jr, Hilton J, Bigner DD (1989) Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. J Natl Cancer Inst 81: 524Google Scholar
  22. 22.
    Friedman HS, Colvin OM, Aisaka K, Popp J, Bossen EH, Reimer KA, Powell JB, Hilton J, Gross SS, Levi R, Bigner DD, Griffith OW (1990) Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 50: 2455Google Scholar
  23. 23.
    Gibbons GR, Wyrick S, Chaney SG (1989) Rapid reduction of tetrachloro-DL-trans-1,2-diamminocyclohexaneplatinum-IV tetraplatin in RPMI 1640 tissue culture medium. Cancer Res 49: 1402Google Scholar
  24. 24.
    Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF (1984) Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 44: 5427Google Scholar
  25. 25.
    Griffith OW (1982) Mechanism of action, metabolism and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257: 13704Google Scholar
  26. 26.
    Griffith OW (1985) Glutathione and cell survival. In: Sebashi S (ed) Cellular regulation and malignant growth. Japanese Scientific Society Press, Springer, Tokyo, p 292Google Scholar
  27. 27.
    Griffith OW, Meister A (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254: 7558Google Scholar
  28. 28.
    Groothiuis DR, Blasberg RG (1985) Rational brain tumor chemotherapy: the interaction of drug and tumor. Neurol Clin 3: 810Google Scholar
  29. 29.
    Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsurno T, Grotzinger KR, McKoy WM, Young RC, Ozols RF (1985) Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and-sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34: 2583Google Scholar
  30. 30.
    Herman TS, Teicher BA, Holden SA, Pfeffer MR, Jones SM (1990) Addition of 2-nitroimidazole radiosensitizers to trimodality therapy (cis-diamminedichloroplatinum II/hyperthermia/radiation) in the murine FSaIIC fibrosarcoma. Cancer Res 50: 2734Google Scholar
  31. 31.
    Hirata J, Kikuchi Y, Kita T, Imaizumi E, Tode T, Ishii K, Kudoh K, Nagata I (1993) Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S, R-sulfoximine. Int J Cancer 55: 521Google Scholar
  32. 32.
    Jocelyn PC, Kamminga A (1970) Development of fluorescence between o-phthaldialdehyde and thiols. Anal Biochem 37: 417Google Scholar
  33. 33.
    Johnson SW, Ozols RF, Hamilton TC (1993) Mechanisms of drug resistance in ovarian cancer. Cancer 71: 644Google Scholar
  34. 34.
    Kavanagh JJ (1990) Carboplatin in refractory epithelial ovarian cancer. In: Bunn PA, Canetta R, Ozols RF, Rozencweig M (eds) Carboplatin (JM-8): current perspectives and future directions. Harcourt Brace Jovanovich, Philadelphia, p 141Google Scholar
  35. 35.
    Kendall D, Alberts D, Peng YW (1989) Activity of tetraplatin isomers against cisplatin sensitive and resistant human tumor cell lines. Proc Amer Assoc Cancer Res 30: 469Google Scholar
  36. 36.
    Kramer RA, Schuller HM, Smith AC, Boyd MR (1985) Effects of buthionine sulfoximine on the nephrotoxicity of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosurea (MeCCNU). J Pharmacol Exp Ther 234: 498Google Scholar
  37. 37.
    Kramer RA, Greene K, Ahmad S, Vistica DT (1987) Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res 47: 1593Google Scholar
  38. 38.
    Laderoute KR, Eryavec E, McClelland RA, Rauth AM (1986) The production of strand breaks in DNA in the presence of the hydroxylamine of SR-2508 (1-[N-(2-hydroxyethyl)acetamido]-2-nitroimidazole). Int J Radiat Oncol Biol Phys 12: 1215Google Scholar
  39. 39.
    Lee FYF, Allalunis-Turner MJ, Siemann DW (1987) Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine. Br J Cancer 50: 33Google Scholar
  40. 40.
    McNally NJ (1982) Enhancement of chemotherapy agents. Int J Radiat Oncol Biol Phys 8: 593Google Scholar
  41. 41.
    Meister A (1983) Metabolism and transport of glutathione and other γ-glutamyl compounds. In: Larson A, Orrenius S, Holmgren A, Mannervik B (eds) Functions of glutathione: biochemical, physiological, toxicological, and clinical aspects. Raven Press, New York, p 1Google Scholar
  42. 42.
    Mistry P, Harrap R (1991) Historical aspects of glutathione and cancer chemotherapy. Pharmacol Ther 49: 125Google Scholar
  43. 43.
    Mistry P, Loh SY, Kelland LR, Harrap KR (1993) Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Int J Cancer 55: 848Google Scholar
  44. 44.
    Mizutani Y, Bonavida B (1993) Overcoming TNF-α and CDDP resistance of a human ovarian cancer cell line (C30) by treatment with buthionine sulfoximine in combination with TNF-α and/or CDDP. Int J Oncol 3: 229Google Scholar
  45. 45.
    Mulcahy RT, Tutsch KD, Pomplun M, Arzoomanian RZ, Alberti D, Feierabend C, Bailey HH (1994) The pharmacodynamics of S, R-buthionine sulfoximine (BSO) given as a 24–48-hour continuous infusion in patients undergoing phase I treatment with iv melphalan and BSO. Proc Am Assoc Cancer Res 35: 377Google Scholar
  46. 46.
    Orr RM, O'Neil CF, Murrer BA, Nicholson MC, Harrap KR (1989) Evaluation of novel platinum II and platinum IV ammine/amine complexes using L1210 sublines resistant to cisplatin or tetraplatin. Proc Am Assoc Cancer Res 30: 509Google Scholar
  47. 47.
    Ozols RF (1992) Advances in the chemotherapy of gynecologic malignancies. Hematol Oncol 10: 43Google Scholar
  48. 48.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC (1987) Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 36: 147Google Scholar
  49. 49.
    Ozols RF, O'Dwyer PJ, Hamilton TC (1993) Clinical reversal of drug resistance in ovarian cancer. Gynecol Oncol 51: 90Google Scholar
  50. 50.
    Panneerselvam M, Rahman A (1989) Molecular mechanisms of resistance of human ovarian cancer cells to cisplatin and tetraplatin. Proc Amer Assoc Cancer Res 30: 523Google Scholar
  51. 51.
    Perez RP, Hamilton TC, Ozols RF (1990) Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 48: 19Google Scholar
  52. 52.
    Rahman A, Roh JK, Wolpert-DeFilippes MK, Golden A, Venditti JM, Woolley PV (1988) Therapeutic and pharmacological studies of tetrachloro(D,L-trans)1,2-diamminocyclohexane platinum (IV) (tetraplatin), a new platinum analog. Cancer Res 48: 1745Google Scholar
  53. 53.
    Roizen-Towle L, Hall EJ, Piro JP (1986) Oxygen dependence for chemosensitization by misonidazole. Br J Cancer 54: 919Google Scholar
  54. 54.
    Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55: 2303Google Scholar
  55. 55.
    Rozencweig M, Martin A, Beltangady M, Bragman K, Goodlow J, Wiltshaw E, Calvert H, Mangioni C, Pecorelli S, Bolis G, Rocker I, Adams M, Canetta R (1990). In: Bunn, PA, Canetta, R, Ozols RF, Rozencweig M (eds) Carboplatin (JM-8): current perspectives and future directions. Harcourt Brace Jovanovich, Philadelphia, p 175Google Scholar
  56. 56.
    Russo A, DeGraft W, Friedman N, Mitchell JB (1986) Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 46: 2845Google Scholar
  57. 57.
    Russo A, Tochner L, Phillips T, Carmichael J, DeGraff W, Friedman N, Fisher J, Mitchell JB (1986) In vivo modulation of glutathione by buthionine sulfoximine: effect on marrow response to melphalan. Int J Radiat Oncol Biol Phys 12: 1187Google Scholar
  58. 58.
    Shulman LN, Buswell L, Goodman H, Muto M, Berkowitz R, Teicher B, Kusumoto T, Hurwitz SJ, Kalish LA, Coleman CN (1994) Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer. Int J Radiat Oncol Biol Phys 29: 545Google Scholar
  59. 59.
    Siemann DW (1984) Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 10: 1585Google Scholar
  60. 60.
    Siemann DW, Beyers KL (1993) In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Br J Cancer 68: 1071Google Scholar
  61. 61.
    Skapek S, Colvin OM, Griffith O, Elion GB, Bigner DD, Friedman HS (1988) Enhanced melphalan cytotoxicity following butathionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res 48: 2764Google Scholar
  62. 62.
    Skapek SX, Colvin OM, Griffith OW, Groothuis DR, Colapinto EV, Lee Y, Hilton J, Elion GB, Bigner DD, Friedman HS (1988) Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts. Biochem Pharmacol 37: 4313Google Scholar
  63. 63.
    Smith JH, Smith MA, Litterst CL, Copley MP, Uozumi J, Boyd MR (1988) Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat. Fundam Appl Toxicol 10: 45Google Scholar
  64. 64.
    Smith MA, Smith JH, Litterst CL, Copley MP, Uozumi J, Boyd MR (1988) In vivo biochemical indexes of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat. Fundam Appl Toxicol 10: 62Google Scholar
  65. 65.
    Soble MJ, Dorr RT (1987) Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice. Res Commun Chem Pathol Pharmacol 55: 161Google Scholar
  66. 66.
    Somfai-Relle S, Suzukake K, Vistica BP, Vistica DT (1984) Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem Pharmacol 33: 485Google Scholar
  67. 67.
    Speyer JL, Richards D, Beller U, Colombo N, Sorich J, Wernz J, Hochster H, Porges R, Muggia F, Canetta R, Beckman EM (1990) Trials of intraperitoneal carboplatin in patients with refractory ovarian cancer. In: Bunn PA, Canetta R, Ozols RF, Rozencweig M (eds) Carboplatin (JM-8): current perspectives and future directions. Harcourt Brace Jovanovich, Philadelphia, p 153Google Scholar
  68. 68.
    Summerhayes IC, Lampidis TJ, Bernal SD, Nadakavukaren JJ, Nadakavukaren KK, Shepard EL, Chen LB (1982) Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci 79: 5292Google Scholar
  69. 69.
    Teicher BA, Frei EI (1988) Development of alkylating agent resistant human tumor cell lines. Cancer Chemother Pharmacol. 21: 292Google Scholar
  70. 70.
    Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E III (1987) Characterization of a human squamous carcinoma cell line resistant tocis-diamminedichloroplatinum(II). Cancer Res 47: 388Google Scholar
  71. 71.
    Teicher BA, Crawford JM, Holden SA, Lin Y, Cathcart KNS, Luchette CA, Flatow J (1988) Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide Cancer 62: 1275Google Scholar
  72. 72.
    Teicher BA, Herman TS, Holden SA, Jones SM (1989) Addition of misonidazole, etanidazole, or hyperthermia to treatment with Fluosol-DA/carbogen/radiation. J Natl Cancer Inst 12: 929Google Scholar
  73. 73.
    Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS (1989) Influence of scheduling on two-drug combinations of alkylating agents in vivo. Cancer Chemother Pharmacol 25: 161Google Scholar
  74. 74.
    Teicher BA, Herman TS, Holden SA (1991) Effect of pH oxygenation and temperature on the cytotoxicity and radiosensitization by etanidazole. Int J Radiat Oncol Biol Phys 20: 723Google Scholar
  75. 75.
    Teicher BA, Herman TS, Shulman L, Bubley G, Coleman CN, Frei III E (1991) Combination of etanidazole with cyclophosphamide and platinum complexes. Cancer Chemother Pharmacol 28: 153Google Scholar
  76. 76.
    Teicher BA, Holden SA, Herman TS, Alvarez Sotomayor E, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E III (1991) Characteristics of five human tumor cell lines and sublines resistant tocis-diamminedichloroplatinum(II). Int J Cancer 47: 252Google Scholar
  77. 77.
    Teicher BA, Holden SA, Herman TS, Frei E III (1991) Strategies for increasing the efficacy of and overcoming resistance to platinum complexes in vivo. In: Howell SB (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum Press, New York, p 295Google Scholar
  78. 78.
    Teicher BA, Pfeffer MR, Alvarez Sotomayor E, Herman TS (1991) DNA crosslinking and pharmacokinetic parameters in target tissues withcis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia. Int J Hyperthermia 7: 773Google Scholar
  79. 79.
    Varnes ME, Biaglow JE (1979) Interactions of the carcinogen 4-nitroquinoline 1-oxide with the nonprotein thiols of mammalian cells. Cancer Res 39: 2960Google Scholar
  80. 80.
    Warnke PC, Friedman HS, Bigner DD, Groothiuis DR (1987) Simultaneous measurements of blood flow and blood-to-tissue transport in xenotransplanted medulloblastomas. Cancer Res 47: 1687Google Scholar
  81. 81.
    Wilkoff LJ, Dulmadge EA, Trader MW, Harrison SD, Griswold DP Jr (1987) Evaluation oftrans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive tocis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 20: 96Google Scholar
  82. 82.
    Wong TW, Whitmore GF (1977) A comparison of radiationsensitizing ability and cell uptake for NDPP and Ro-07-0582. Radiat Res 71: 132Google Scholar
  83. 83.
    Zwelling LA, Kohn KW, Ross WE, Ewig RAG, Anderson T (1978) Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated withcis- andtrans-diamminedichloroplatinum(II). Cancer Res 38: 1762Google Scholar
  84. 84.
    Zwelling LA, Anderson T, Kohn KW (1979) DNA-protein and interstrand cross-linking bycis- andtrans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39: 365Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Sandra E. Brooks
    • 1
  • Timothy T. Korbut
    • 2
  • Norman P. Dupuis
    • 2
  • Sylvia A. Holden
    • 2
  • Beverly A. Teicher
    • 2
  1. 1.Department of Obstetrics and Gynecology, Division of Gynecological OncologyUniversity of Massachusetts Medical CenterWorcesterUSA
  2. 2.Division of Cancer PharmacologyDana-Farber Cancer Institute and Joint Center for Radiation TherapyBostonUSA

Personalised recommendations